What it's for (Indications)
- BCG vaccine is primarily indicated for the prevention of tuberculosis (TB), especially severe forms such as miliary TB and TB meningitis, particularly in infants and young children residing in areas with a high prevalence of TB, or for individuals at high risk of exposure.
- Its protective efficacy against pulmonary TB in adults is variable but it remains a crucial tool for preventing severe childhood disease.
- Furthermore, the Bacillus Calmette-Guérin (BCG) live attenuated bacterial preparation is also indicated for the intravesical treatment of carcinoma in situ (CIS) of the urinary bladder and as prophylaxis for primary or recurrent superficial papillary tumors of the bladder following transurethral resection (TUR).
- This intravesical application leverages the immunomodulatory properties of BCG to elicit a localized anti-tumor immune response within the bladder.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For tuberculosis prevention, BCG vaccine is administered as a single intradermal injection, typically in the deltoid region of the upper arm. The precise dose (e.g., 0.05 mg or 0.1 mg reconstituted in saline) can vary depending on the manufacturer and the specific strain of BCG used. It is generally given as early as possible after birth in high-endemic regions. For the intravesical treatment of bladder cancer, the dosage and administration regimen are distinct and more complex. Typically, a specified amount of reconstituted BCG is instilled directly into the bladder via a catheter and retained for approximately two hours. A common regimen involves weekly instillations for six consecutive weeks, followed by maintenance therapy with reduced frequency over several months or years, depending on the patient's response and disease recurrence risk. Strict aseptic technique is critical for both routes of administration. |
Safety & Warnings
Common Side Effects
- Side effects associated with BCG vaccination are predominantly local reactions at the injection site, including the formation of a papule that may ulcerate and subsequently heal, leaving a characteristic permanent scar.
- Regional lymphadenitis (swelling of lymph nodes near the injection site) is also common.
- Less frequently, systemic reactions such as low-grade fever, malaise, or headaches may occur.
- Rarely, more severe complications include disseminated BCG infection (BCG-itis), osteitis, or osteomyelitis, primarily in immunocompromised individuals.
- For intravesical BCG therapy for bladder cancer, common side effects include cystitis-like symptoms (e.
- g.
- , dysuria, urinary frequency, urgency, hematuria), flu-like symptoms (fever, chills, malaise), and nausea.
- More serious, albeit rare, complications of intravesical therapy can include systemic BCG infection leading to sepsis, granulomatous prostatitis, epididymitis, acute renal tubular necrosis, and arthralgia, necessitating prompt medical intervention.
Serious Warnings
- Black Box Warning: **Serious Warnings** BCG (Bacillus Calmette-Guérin) vaccine, whether administered intradermally for tuberculosis prevention or intravesically for bladder cancer, carries significant risks, particularly in vulnerable populations. **Disseminated BCG Infection (BCG-itis) in Immunocompromised Individuals:** Administration of live attenuated BCG to individuals with compromised immune systems (e.g., HIV infection, congenital immunodeficiency, or those receiving immunosuppressive therapies such as high-dose corticosteroids, chemotherapy, or radiation) carries a high risk of developing severe, disseminated BCG infection, which can be life-threatening. Prior to administration, thorough evaluation of immune status is critical. **Systemic BCG Infection Following Intravesical Therapy:** Intravesical administration of BCG for bladder cancer can lead to severe systemic BCG infection (BCG-itis), sepsis, or even death, particularly if there is compromise of the bladder mucosa (e.g., recent transurethral resection, traumatic catheterization, or active hematuria), allowing systemic absorption. Patients experiencing fever, chills, severe malaise, or other signs of systemic illness after intravesical BCG must be immediately evaluated and treated for potential disseminated infection. Strict adherence to contraindications and administration guidelines is paramount to mitigate these grave risks.
- Serious warnings associated with BCG vaccine primarily revolve around the risk of disseminated BCG infection, particularly in individuals with compromised immune systems, including those with HIV infection, congenital immunodeficiency disorders, or those undergoing immunosuppressive therapy (e.
- g.
- , high-dose corticosteroids, chemotherapy, radiation).
- BCG should not be administered to pregnant women due to its live attenuated nature.
- Care must be taken to ensure intradermal administration, as subcutaneous injection can increase the risk of local abscess formation.
- Vaccination can complicate the interpretation of subsequent tuberculin skin tests (TSTs), as it typically induces a positive reaction.
- For intravesical BCG therapy, a heightened risk of systemic BCG infection (BCG-itis) exists if the bladder epithelium is compromised (e.
- g.
- , recent bladder trauma, transurethral resection, or traumatic catheterization), allowing systemic absorption.
- Patients experiencing significant fever, severe flu-like symptoms, or other signs of systemic illness following intravesical BCG require immediate evaluation for disseminated infection.
- Concurrent urinary tract infections or gross hematuria are contraindications for intravesical instillation due to increased absorption risk.
How it Works (Mechanism of Action)
As a live attenuated vaccine, BCG induces cell-mediated immunity against *Mycobacterium tuberculosis* by mimicking a natural mycobacterial infection. The attenuated *Mycobacterium bovis* strain replicates within the host's macrophages and dendritic cells, presenting mycobacterial antigens to the immune system. This process stimulates a robust T-cell response, including CD4+ and CD8+ T lymphocytes, and activates macrophages, leading to the formation of granulomas characteristic of TB immunity. This cellular immune response is crucial for controlling and clearing mycobacterial infections. For its intravesical use in bladder cancer, BCG's mechanism involves a potent, localized immunomodulatory effect. It adheres to and is internalized by bladder epithelial cells and tumor cells, triggering an intense inflammatory reaction and immune response within the bladder wall. This response involves the recruitment and activation of various immune cells, including T-lymphocytes, macrophages, and natural killer (NK) cells. The release of cytokines (e.g., IL-1, IL-2, IL-6, IL-8, TNF-α, IFN-γ) from these activated cells is thought to mediate direct cytotoxic effects on tumor cells and inhibit tumor growth, ultimately leading to tumor regression or prevention of recurrence. The exact complete cascade of events leading to tumor destruction is still under active research but is undeniably immune-mediated.